{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:23:03Z","timestamp":1782814983445,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.adro.2022.101143","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T18:30:56Z","timestamp":1670697056000},"page":"101143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5384-1637","authenticated-orcid":false,"given":"Brady S.","family":"Laughlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly M.","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A.S.","family":"Toesca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Golafshar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer R.","family":"Keole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Rwigema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Schild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad J.","family":"Stish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"DeWees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2022.101143_bib0001","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.2008.18.9563","article-title":"Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02\/AUO AP 09\/95","volume":"27","author":"Wiegel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0002","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2022.101143_bib0003","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","article-title":"Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial","volume":"181","author":"Thompson","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.adro.2022.101143_bib0004","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): A randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0005","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.adro.2022.101143_bib0006","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101143_bib0007","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijrobp.2005.01.020","article-title":"Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy","volume":"63","author":"Cheung","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101143_bib0008","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1200\/JCO.2016.68.3425","article-title":"Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer","volume":"34","author":"Stish","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0009","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: A prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2022.101143_bib0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijrobp.2022.08.041","article-title":"Quality-of-life outcomes and toxicity profile among patients with localized prostate cancer after radical prostatectomy treated with stereotactic body radiation: The SCIMITAR Multicenter Phase 2 Trial","volume":"115","author":"Ma","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101143_bib0011","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.042","article-title":"LBA49_PR - Timing of radiotherapy (RT) after radical prostatectomy (RP): First results from the RADICALS RT randomised controlled trial (RCT) [NCT00541047]","volume":"30","author":"Parker","year":"2019","journal-title":"Annal Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0012","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): A randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0013","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): A randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0014","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): A randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2022.101143_bib0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): Late toxicity results from a randomised, non-inferiority, phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0016","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0017","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ijrobp.2014.01.015","article-title":"Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: Results from a randomized trial","volume":"88","author":"Hoffman","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101143_bib0018","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.ijrobp.2020.11.009","article-title":"Hypofractionated postprostatectomy radiation therapy for prostate cancer to reduce toxicity and improve patient convenience: A phase 1\/2 trial","volume":"109","author":"Wages","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101143_bib0019","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.ijrobp.2020.12.020","article-title":"Hypofractionated radiation therapy to the prostate bed with intensity-modulated radiation therapy (IMRT): A phase 2 trial","volume":"109","author":"Leite","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101143_bib0020","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijrobp.2021.07.041","article-title":"Primary endpoint analysis of a randomized phase III trial of hypofractionated vs. conventional post-prostatectomy radiotherapy: NRG Oncology GU003","volume":"111","author":"Buyyounouski","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101143_bib0021","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.ijrobp.2014.07.015","article-title":"Hypofractionated IMRT of the prostate bed after radical prostatectomy: Acute toxicity in the PRIAMOS-1 trial","volume":"90","author":"Katayama","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101143_bib0022","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00066-020-01691-z","article-title":"Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: Long-term outcome and pattern of toxicity","volume":"197","author":"Franzese","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.adro.2022.101143_bib0023","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/j.clgc.2017.01.025","article-title":"Moderate hypofractionated postprostatectomy volumetric modulated arc therapy with daily image guidance (VMAT-IGRT): A mono-institutional report on feasibility and acute toxicity","volume":"15","author":"Fersino","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.adro.2022.101143_bib0024","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2022.101143_bib0026","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/COC.0000000000000241","article-title":"Hypofractionated versus standard fractionated proton-beam therapy for low-risk prostate cancer: Interim results of a randomized trial PCG GU 002","volume":"41","author":"Vargas","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0027","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.ijrobp.2007.04.075","article-title":"Rectal dose-volume differences using proton radiotherapy and a rectal balloon or water alone for the treatment of prostate cancer","volume":"69","author":"Vargas","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101143_bib0028","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1756-9966-28-117","article-title":"Modeling of alpha\/beta for late rectal toxicity from a randomized phase II study: Conventional versus hypofractionated scheme for localized prostate cancer","volume":"28","author":"Marzi","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.adro.2022.101143_bib0029","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ijrobp.2004.04.014","article-title":"Fractionation and late rectal toxicity","volume":"60","author":"Brenner","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101143_bib0030","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2012.02.049","article-title":"Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer","volume":"84","author":"Arcangeli","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101143_bib0031","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1200\/JCO.2005.06.153","article-title":"Randomized trial comparing two fractionation schedules for patients with localized prostate cancer","volume":"23","author":"Lukka","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0032","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0033","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ijrobp.2010.07.1984","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: Final results of phase III randomized trial","volume":"81","author":"Yeoh","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101143_bib0034","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.rpor.2016.01.002","article-title":"Image-guided hypofractionated proton beam therapy for low-risk prostate cancer: Analysis of quality of life and toxicity, PCG GU 002","volume":"21","author":"Vargas","year":"2016","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.adro.2022.101143_bib0035","doi-asserted-by":"crossref","DOI":"10.1200\/JOP.2012.000548","article-title":"Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: An emerging initial radiation treatment option for organ-confined prostate cancer","volume":"8","author":"Hodges","year":"2012","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.adro.2022.101143_bib0036","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3390\/cancers14030696","article-title":"Stereotactic radiotherapy after radical prostatectomy in patients with prostate cancer in the adjuvant or salvage setting: A systematic review","volume":"14","author":"Schr\u00f6der","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.adro.2022.101143_bib0037","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijrobp.2018.12.047","article-title":"Phase 1 trial of SBRT to the prostate fossa after prostatectomy","volume":"104","author":"Ballas","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101143_bib0038","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijrobp.2019.11.005","article-title":"Stereotactic body radiation therapy to the prostate bed: Results of a phase 1 dose-escalation trial","volume":"106","author":"Sampath","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101143_bib0039","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0040","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.clon.2016.04.040","article-title":"Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences","volume":"28","author":"Ost","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.adro.2022.101143_bib0041","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","article-title":"Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: Amulti-institutional analysis","volume":"69","author":"Ost","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2022.101143_bib0042","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ijrobp.2016.01.032","article-title":"Stereotactic body radiation therapy for oligometastatic prostate cancer","volume":"95","author":"Muldermans","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101143_bib0043","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.prro.2013.05.006","article-title":"Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases","volume":"4","author":"Owen","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0044","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/COC.0b013e3182610878","article-title":"Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer","volume":"37","author":"Jereczek-Fossa","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0045","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1748-717X-9-135","article-title":"Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence","volume":"9","author":"Decaestecker","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0046","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clgc.2012.08.003","article-title":"Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: Deferring androgen deprivation therapy","volume":"11","author":"Berkovic","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.adro.2022.101143_bib0047","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): An international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2022.101143_bib0048","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2022.101143_bib0049","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422002494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422002494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:43:37Z","timestamp":1762530217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109422002494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2452109422002494"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2022.101143","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2022.101143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101143"}}